Diagnosis and treatment of clear cell hidradenocarcinoma of the scalp

Abstract

Clear cell hidradenocarcinoma (CCH) is an exceedingly rare and highly malignant tumor of the eccrine sweat glands. Its treatment is extremely difficult due to the characteristically aggressive clinical course including repeated local recurrence and uncontrollable distal metastasis coming along with a very poor prognosis. Most published case studies recommend a wide surgical excision followed by adjuvant conservative therapy, which is generally considered to be the standard treatment. Two cases of nodular CCH of the scalp either presenting as a singular primary lesion or at an already metastatic stage were analyzed retrospectively. Wide local excision of the tumor couldn’t prevent the primary carcinoma from recurring and metastasizing. Both cases received various therapies but the results were unsatisfactory. Although most authors have recommended that early wide surgical excision of the tumor is a feasible therapeutic measurement, our results raise doubts on the efficacy of this treatment strategy. As alternative approaches (i.e. chemotherapy, radiotherapy) are similarly controversial, further studies and a wide exchange of clinical experiences are crucial.

Keywords

hidradenocarcinoma / scalp / diagnosis / treatment

References

[1] McCalmontT.H.. A call for logic in the classification of adnexal neoplasms. Am J Dermatopathol, 1996, 18(2): 103-109

[2] MessingM.J., RichardsonM.S., SmithM.T., et al.. Metastatic clear-cell hidradenocarcinoma of the vulva. Gynecol Oncol, 1993, 48(2): 264-268

[3] LongW.P., DupinC., LevineE.A.. Recurrent malignant acrospiroma. Treatment by chest wall excision. Dermatol Surg, 1998, 24(8): 908-912

[4] MehreganA.H., HashimotoK., RahbariH.. Eccrine adenocarcinoma. A clinicopathologic study of 35 cases. Arch Dermatol, 1983, 119(2): 104-114

[5] CruzD.J.. Sweat gland carcinomas: a comprehensive review. Semin Diagn Pathol, 1987, 4(1): 38-74

[6] KeasbeyL.E., HadleyG.G.. Clear cell hidradenoma: report of three cases with widespread metastases. Cancer, 1954, 7(5): 934-952

[7] Hernandez-PerezE., Cestoni-ParducciR.. Nodular hidradenoma and hidradenocarcinoma. A 10-year review. J Am Acad Dermatol, 1985, 12(1Pt1): 15-20

[8] YavelR., HinshawM., RaoV., et al.. Hidradenomas and a hidradenocarcinoma of the scalp managed using Mohs micrographic surgery and a multidisciplinary approach: case reports and review of the literature. Dermatol Surg, 2009, 35(2): 273-281

[9] GortlerI., KopplH., StarkG.B., et al.. Metastatic malignant acrospiroma of the hand. Eur J Surg Oncol, 2001, 27(4): 431-435

[10] LimS.C., LeeM.J., LeeM.S., et al.. Giant hidradenocarcinoma: a report of malignant transformation from nodular hidradenoma. Pathol Int, 1998, 48(10): 818-823

[11] MassadL.S., BittermanP., Clarke-PearsonD.L.. Metastatic clear cell eccrine hidradenocarcinoma of the vulva: survival after primary surgical resection. Gynecol Oncol, 1996, 61(2): 287-290

[12] Lopez-BurbanoL.F., CimorraG.A., Gonzalez-PeironaE., et al.. Malignant clear-cell hidradenoma. Plast Reconstr Surg, 1987, 80(2): 300-303

[13] HeadingtonJ.T., NiederhuberJ.E., BealsT.F.. Malignant clear cell acrospiroma. Cancer, 1978, 41(2): 641-647

[14] NashJ.W., BarrettT.L., KiesM., et al.. Metastatic hidradenocarcinoma with demonstration of Her-2/neu gene amplification by fluorescence in situ hybridization: potential treatment implications. J Cutan Pathol, 2007, 34(1): 49-54

[15] JouaryT., KaiafaA., LipinskiP., et al.. Metastatic hidradenocarcinoma: efficacy of capecitabine. Arch Dermatol, 2006, 142(10): 1366-1367

[16] BognerP.N., FullenD.R., LoweL., et al.. Lymphatic mapping and sentinel lymph node biopsy in the detection of early metastasis from sweat gland carcinoma. Cancer, 2003, 97(9): 2285-2289

[17] WildemoreJ.K., LeeJ.B., HumphreysT.R.. Mohs surgery for malignant eccrine neoplasms. Dermatol Surg, 2004, 30(12Pt2): 1574-1579

[18] OhtaM., HiramotoM., FujiiM., et al.. Nodular hidradenocarcinoma on the scalp of a young woman: case report and review of literature. Dermatol Surg, 2004, 30(9): 1265-1268

[19] JohnsonB.L.Jr, HelwigE.B.. Eccrine acrospiroma. A clinicopathologic study. Cancer, 1969, 23(3): 641-657

[20] DzubowL.M.. Chemosurgical report: a nongeometric approach to wound closure following Mohs surgery. J Dermatol Surg Oncol, 1986, 12(4): 342-345

[21] KoC.J., CochranA.J., EngW., et al.. Hidradenocarcinoma: a histological and immunohistochemical study. J Cutan Pathol, 2006, 33(11): 726-730

[22] WongT.Y., SusterS., NogitaT., et al.. Clear cell eccrine carcinomas of the skin. A clinicopathologic study of nine patients. Cancer, 1994, 73(6): 1631-1643

[23] ReyesC.V.. Clear cell hidradenocarcinoma developing in pacemaker pocket. Pacing Clin Electrophysiol, 2008, 31(11): 1513-1515

[24] HeydermanE., GrahamR.M., ChapmanD.V., et al.. Epithelial markers in primary skin cancer: an immunoperoxidase study of the distribution of epithelial membrane antigen (EMA) and carcinoembryonic antigen (CEA) in 65 primary skin carcinomas. Histopathology, 1984, 8(3): 423-434

[25] KuoT.. Clear cell carcinoma of the skin. A variant of the squamous cell carcinoma that simulates sebaceous carcinoma. Am J Surg Pathol, 1980, 4(6): 573-583

[26] McGregorD.K., KhuranaK.K., CaoC., et al.. Diagnosing primary and metastatic renal cell carcinoma: the use of the monoclonal antibody ‘Renal Cell Carcinoma Marker’. Am J Surg Pathol, 2001, 25(12): 1485-1492

[27] ParkH.J., KimY.C., CinnY.W.. Nodular hidradenocarcinoma with prominent squamous differentiation: case report and immunohistochemical study. J Cutan Pathol, 2000, 27(8): 423-427

[28] HarariP.M., ShimmD.S., BangertJ.L., et al.. The role of radiotherapy in the treatment of malignant sweat gland neoplasms. Cancer, 1990, 65(8): 1737-1740